Attenuated dose Rituximab with ChemoTherapy In CLL: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)

Registry ID

EUCTR2009-010998-20

Source registry

EUCTR

Status

GB - no longer in EU/EEA

Phase

PHASE4

Sponsor

Leeds Teaching Hospitals NHS Trust

Start date

2009-05-01

Last update

2026-08-16

Conditions

• Chronic Lymphocytic Leukaemia

Summary

To compare the complete response (CR) rates as defined by IWCLL criteria in each treatment group.

Locations

• , , UK

Related clinical trials

• Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure
• A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
• Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
• Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy

View on source registry